Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844700 | 0.79 | DPP4 (0.57) | DPP4MAPTKCNH2FAPDPP8 | |
| SCHEMBL3843422 | 0.78 | PARP1 (0.42) | DPP4SMN1; SMN2KCNH2DPP7 | |
| SCHEMBL3839829 | 0.78 | DPP4 (0.35) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3848266 | 0.75 | DPP4 (0.60) | MEN1KMT2ACNR1DPP4FAP | |
| SCHEMBL27153157 | 0.74 | HSD17B10 (0.54) | LMNAMEN1KMT2ADPP4MAPT | |
| SCHEMBL29165136 | 0.74 | HSD17B10 (0.54) | LMNAMEN1KMT2ADPP4MAPT | |
| SCHEMBL2846468 | 0.73 | KDM4E (0.55) | LMNAMEN1KMT2AMAPTTP53 | |
| SCHEMBL8237255 | 0.71 | HSD17B10 (0.36) | DPP4FAPDPP7PIK3CA | |
| SCHEMBL30020013 | 0.70 | HSD17B10 (0.48) | LMNADPP4MAPTTP53THRB | |
| Hydrochloric Acid SCHEMBL30019565 | 0.69 | HSD17B10 (0.46) | LMNAMAPTTP53THRBUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116541-B1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2116541-A1 | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | Pfizer Products Incorporated (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256310-A1 | Therapeutic compounds | REN, SLC5A1, SLC5A2 | LMNA 1574/4885MEN1 1708/4885KMT2A 4088/4885 |
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | LMNA 2178/4885MEN1 537/4885KMT2A 2117/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | LMNA 2178/4885MEN1 537/4885KMT2A 2117/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | LMNA 2178/4885MEN1 537/4885KMT2A 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.